The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
The Brown University spinout plans to market its instrument, Nabsys HD-Mapping, for genome mapping, de novo assembly, and structural variant detection.
The researchers noted that 93 of the newly identified loci are found in both African-American and European populations, and only 18 are European-specific.
The team's assembly represents 95 percent of the genomic sequence of barley, the most complete version of that genome to date.
An Australian team has sequenced and mapped the genome of a prostate cancer tumor, as the Australian Financial Review reports.
At AGBT, an early adopter of Bionano's technology discussed how his lab is using it in conjunction with NGS to diagnose rare diseases.
The company's Irys genome mapping technology provides researchers with a non-sequencing-based tool that is essential for studying structural variation.
The public-private consortium, led by the National Institute of Standards and Technology, recently released four new reference materials.
At a workshop organized by the Genome in a Bottle consortium last month, Nabsys presented its human genome maps for the first time.
BioNano plans to develop structural variant assays on its Irys system for diagnostic use in China as a first step in bringing its technology to the clinic.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.